No Data
No Data
Express News | Matinas BioPharma Says New In Vitro Data Showing LNC Platform Delivering Small Oligonucleotides Presented At TIDES USA 2024
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
Buy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal Candidate
Q1 2024 Matinas BioPharma Holdings Inc Earnings Call
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
Express News | Matinas BioPharma Holdings Inc - Recent $10 Mln Financing Expected to Fund Planned Development Programs and Operations Into Q2 of 2025
No Data